Drug Profile
Amlodipine/chlortalidone/telmisartan - Yuhan
Alternative Names: Amlodipine/telmisartan/chlortalidone; Chlortalidone/amlodipine/telmisartan; Chlortalidone/telmisartan/amlodipine; Telmisartan/amlodipine/chlortalidone; Telmisartan/chlortalidone/amlodipine; YH 22162; YH22162 FDCLatest Information Update: 20 Sep 2023
Price :
$50
*
At a glance
- Originator Yuhan
- Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Ischaemic heart disorder therapies; Isoindoles; Small molecules; Sulfonamides
- Mechanism of Action ACE inhibitors; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Hypertension
Most Recent Events
- 20 Sep 2023 Amlodipine/chlortalidone/telmisartan is still in Preregistration phase for Hypertension in South Korea
- 08 Oct 2021 No development reported - Preregistration for Hypertension (Treatment-experienced) in South Korea (PO)
- 20 Feb 2019 Amlodipine/chlortalidone/telmisartan is still in phase III trial for Hypertension in South Korea